Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics

Caris Life Sciences, the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, announced a new agreement with Moderna in support of Moderna's oncology and novel therapeutics initiatives.

Through this multi-year agreement, Moderna will leverage Caris' vast library of de-identified, multi-modal data solutions derived from whole exome sequencing, whole transcriptome sequencing and protein analyses along with claims data to enhance development strategies for Moderna's oncology pipeline, including facilitation of optimal clinical trial design, discovery of novel biomarkers and characterization of resistance mechanisms.